← All trials
NCT03929601
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2019
- Primary completion
- Jul 31, 2025
- Completion date
- Jul 31, 2026
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead sponsor
- National Institutes of Health (NIH)Collaborator
- Juvenile Diabetes Research FoundationCollaborator
- Type 1 Diabetes TrialNetStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.